Hedgehog inhibitors: A patent review (2013-present)

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 5, 2015, Pages 549-565

  Xin, Minhang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Basal cell carcinoma; Cancer; Hedgehog signaling pathway; Inhibitors; Patent

Indexed keywords

ANTINEOPLASTIC AGENT; BMS 833923; CYCLOPEPTIDE; G PROTEIN COUPLED RECEPTOR; GLASDEGIB; NTW 3729; NVP LEQ 506; PATIDEGIB; PF 5274857; PROTEIN INHIBITOR; SEN 794; SONIC HEDGEHOG PROTEIN; SONIC HEDGEHOG PROTEIN INHIBITOR; SONIDEGIB; SULFONAMIDE; TALADEGIB; UNCLASSIFIED DRUG; VISMODEGIB; ANILIDE; PYRIDINE DERIVATIVE;

ADVANCED CANCER; ANTIPROLIFERATIVE ACTIVITY; BASAL CELL CARCINOMA; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; IC50; LUNG CARCINOMA; MEDULLOBLASTOMA; NEOPLASM; NONHUMAN; PANCREAS CARCINOMA; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG EFFECTS; NEOPLASMS; PATENT; PATHOLOGY;

ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HEDGEHOG PROTEINS; HUMANS; NEOPLASMS; PATENTS AS TOPIC; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 84928328628     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2015.1019864     Document Type: Review

References (101)

1. Rask-Anderson M, Zhang J, Fabbro D, et al. Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci 2014;35:604-20
2. Ng JM, Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer 2011;11:493-501
3. Ruch JM, Kim EJ. Hedgehog signaling pathway and cancer therapeutics: progress to date. Drugs 2013;73:1-11
4. Onishi H, Katano M. Hedgehog signaling pathway as therapeutic target in various types of cancer. Cancer Sci 2011;102:1756-60
5. Mahindroo N, Punchihewa C, Fujii N. Hedgehog-Gli signaling pathway inhibitors as anticancer agents. J Med Chem 2009;52:3829-45
6. Tremblay MR, Nesler M, Weatherhead R, et al. Recent patents for hedgehog pathway inhibitors for the treatment of malignancy. Expert Opin Ther Pat 2009;19:1039-56
7. Peukert S, Miller-Moslin K. Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics. ChemMedChem 2010;5:500-12
8. Li Y, Maitah MY, Ahmad A, et al. Targeting the hedgehog signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:49-66
9. Hadden MK. Hedgehog pathway inhibitors: a patent review (2009-present). Expert Opin Ther Pat 2013;23:345-61
10. Banerjee U, Hadden MK. Recent advances in the design of hedgehog pathway inhibitors for the treatment of malignancies. Expert Opin Drug Discov 2014;9:751-71
11. Nusslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in drosophila. Nature 1980;287:795-801
12. Echelard Y, Epstein DJ, St-Jacques B, et al. Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell 1993;75:1417-30
13. Trinh TN, McLaughlin EA, Gordon CP, et al. Hedgehog signaling pathway inhibitors as cancer suppressing agents. Med Chem Comm 2014;5:117-33
14. Rohatgi R, Milenkovic L, Corcoran RB, et al. Hedgehog signal transduction by Smoothened: pharmacological evidence for a 2-step activation process. Proc Natl Acad Sci USA 2009;106:3196-201
15. Tremblay MR, McGovern K, Read MA, et al. New developments in the discovery of small molecule hedgehog pathway antagonists. Curr Opin Chem Biol 2010;10:428-35
16. Rubin LL, de Sauvage FJ. Targeting the hedgehog pathway in cancer. Nat Rev Drug Discov 2006;5:1026-33
17. Scales SJ, de Sauvage FJ. Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009;30:303-12
18. Gupta S, Takebe N, Lorusso P. Targeting the hedgehog pathway in cancer. Ther Adv Med Oncol 2010;2:237-50
19. Amakye D, Jaqani Z, Dorsch M. Unraveling the therapeutic potential of the hedgehog pathway in cancer. Nat Med 2013;19:1410-22 . This report marks the review of hedgehog pathway and its therapeutic potential for cancer therapy.
20. Gould A, Missailidis S. Targeting the hedgehog pathway: the development of cyclopamine and the development of anti-cancer drugs targeting the hedgehog pathway. Mini Rev Med Chem 2011;11:200-13
21. Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 2005;152:43-51
22. Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012;488:106-10
23. Jones DT, Jager N, Kool M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012;488:100-5
24. Rajurkar M, Huang H, Cotton JL, et al. Distinct cellular origin and genetic requirement of Hedgehog-Gli in postnatal rhabdomyosarcoma genesis. Oncogene 2014;33:5370-8
25. Hettmer S, Teot LA, van Hummelen P, et al. Mutations in Hedgehog pathway genes in fetal rhabdomyomas. J Pathol 2013;231:44-52
26. Singh S, Wang Z, Liang FD, et al. Hedgehog-producing cancer cells respond to and require autocrine Hedgehog activity. Cancer Res 2011;71:4454-63
27. Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008;455:406-10
28. Dierks C, Grbic J, Zirlik K, et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007;13:944-51
29. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011;17:313-19
30. Merchant AA, Matsui W. Targeting Hedgehog-A cancer stem cell pathway. Clin Cancer Res 2010;16:3130-40
31. Teperino R, Aberger F, Esterbauer H, et al. Canonical and non-canonical hedgehog signaling and the control of metabolism. Semin Cell Dev Biol 2014;33:81-92
32. Teperino R, Amann S, Bayer M, et al. Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat. Cell 2012;151:414-26
33. Eberl M, Klingler S, Mangelberger D, et al. Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumor-initiating pancreatic cancer cells. EMBO Mol Med 2012;4:218-33
34. Nolan-Stevaux O, Lau J, Truitt ML, et al. Gli1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 2009;23:24-36
35. Brennan D, Chen X, Cheng L, et al. Noncanonical hedgehog signaling. Vitam Horm 2012;88:55-72
36. Robarge KD, Brunton SA, Castanedo GE, et al. GDC-0449-A potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 2009;19:5576-81 . This paper describes the structure and its design for the first approved hedgehog inhibitor vismodegib.
37. Lyons TG, O'Kane GM, Kelly CM. Efficacy and safety of vismodegib: a new therapeutic agents in the treatment of basal cell carcinoma. Expert Opin Drug Saf 2014;13:1125-32
38. A search results of the clinical information for GDC-0449(Vismodegib) ongoing. Available from: http://www. clinicaltrials.gov/ct2/results? term=vismodegib&Search=Search
39. Pan S, Wu X, Jiang J, et al. Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Med Chem Lett 2010;1:130-4 . This paper describes the discovery of the small molecule sonidegib that inhibited the hedgehog via Smo.
40. Wang C, Wu H, Katritch V, et al. Structure of the human smoothened receptor bound to an antitumor agent. Nature 2013;497:338-43 .. This paper reports the first crystal structure of human Smo receptor bound to the small Smo inhibitor LY2940680.
41. nRocconi RP, Samant L. Methods and compositions for the treatment of ovarian cancer. WO943255; 2013
42. Munchhof MJ, Li Q, Shavnya A, et al. Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med Chem Lett 2012;3:106-11
43. Peukert S, He F, Dai M, et al. Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem 2013;8:1261-5
44. Tremblay MR, Lescarbeau A, Grogan MJ, et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 2009;52:4400-18
45. Allison M. Hedgehog hopes lifted by approval and stung by failure. Nat Biotechnol 2012;30:203
46. Wagner AHP, Okuno S, Eriksson M, et al. Results from a phase 2 randomized, placebo-controlled, double blind study of the hedgehog (HH) pathway antagonist IPI-926 in patients (PTS) with advanced chondrosarcoma (CS). Connective tissue oncology society 18th annual meeting; New York; 2013
47. Ohashi T, Oguro Y, Tanaka T, et al. Discovery of pyrrolo[3,2-c]quinoline-4-one derivatives as novel hedgehog signaling inhibitors. Bioorg Med Chem 2012;20:5496-506
48. Ohashi T, Oguro Y, Tanaka T, et al. Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]quinoline-4-one derivative as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. Bioorg Med Chem 2012;20:5507-17
49. Ishii T, Shimizu Y, Nakashima K, et al. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against vismodegib-resistant smoothened mutant. Eur J Pharmacol 2014;723:305-13
50. Miller-Moslin K, Peukert S, Jain RK, et al. 1-Amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity. J Med Chem 2009;52:3954-68
51. Castanedo GM, Wang S, Robarge KD, et al. Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway. Bioorg Med Chem Lett 2010;20:6748-53
52. Malancona S, Altamura S, Filocamo G, et al. Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl]-N-(1-phenyl-1Hpyrazol-5-yl)hexahydroimidazo[1,5-A] pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in hedgehog pathway dependent malignancies, part 1. Bioorg Med Chem Lett 2011;21:4422-8
53. Kinzel O, Alfieri A, Altamura S, et al. Identification of MK-5710 ((8aS)-8amethyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo-propyl]-N-(1-phenyl-1Hpyrazol-5-yl)hexahydro-imidazo[1,5-A] pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in hedgehog pathway dependent malignancies, part 2. Bioorg Med Chem Lett 2011;21:4429-35
54. Brown ML, Aaron W, Austin RJ, et al. Discovery of amide replacements that improve activity and metabolic stability of a bis-Amide smoothened antagonist hit. Bioorg Med Chem Lett 2011;21:5206-9
55. Ontoria JM, Bufi LL, Torrisi C, et al. Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl] piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors. Bioorg Med Chem Lett 2011;21:5274-82
56. Muraglia E, Ontoria JM, Branca D, et al. N-(2-Alkylaminoethyl)-4-(1,2,4-oxadiazol-5-yl) piperazine-1-carboxamides as highly potent smoothened antagonists. Bioorg Med Chem Lett 2011;21:5283-8
57. Wang J, Jr Mook RA, Lu J, et al. Identification of a novel smoothened antagonist that potently suppresses hedgehog signaling. Bioorg Med Chem Lett 2012;20:6751-7
58. Yang B, Hird AW, Russell DJ, et al. Discovery of novel hedgehog antagonists from cell-based screening: isosteric modification of p38 bisamides as potent inhibitors of SMO. Bioorg Med Chem Lett 2012;22:4907-11
59. Manzetti F, Faure H, Roudaut H, et al. Virtual screening-based discovery and mechanistic characterization of the acylthiourea MRT-10 family of smoothened antagonists. Mol Pharm 2010;78:658-65
60. Solinas A, Faure H, Roudaut H, et al. Acylthiourea, acylurea, and acylquanidine derivatives with potent hedgehog inhibiting activity. J Med Chem 2012;55:1559-71
61. Centre National de la Recherche Scientifique. N-Acylthiourea and Nacylurea inhibitors of the hedgehog protein signalling pathway. WO130422; 2009
62. Centre National de la Recherche Scientifique. Acyl guanidine derivatives modulating the hedgehog protein signaling pathway. WO010013; 2011
63. Manzetti F, Faure H, Roudaut H, et al. Virtual screening-based discovery and mechanistic characterization of the acylthiourea MRT-10 family of smoothened antagonists. Mol Pharm 2010;78:658-65
64. Centre National de la Recherche Scientifique. Novel compounds modulating the hedgehog protein signaling pathway, marked forms thereof, and applications. WO042082; 2013
65. Duke University. Preparation of Smoothened modulators for treatment of proliferative disease. WO043608; 2014
66. Impact Therapeutics, Inc. 4-(3-heteroarylarylamino)quinazoline and 1-(3-heteroarylarylamino) isoquinoline as hedgehog pathway inhibitor and use thereof. WO013614; 2013
67. Impact Therapeutics, Inc. Preparation of N-(3-heteroarylaryl)-4-Arylarylcarboxamides as hedgehog pathway inhibitors for treatment of cancer. WO012511; 2014
68. Jiangsu Simcere Pharmaceutical Co., Ltd. Pyrimidinamines and pyridylamines as inhibitors for hedgehog signaling conduction and their preparation, pharmaceutical compositions and use in the treatment of cancer. CN103864770; 2012
69. Jiangsu Simcere Pharmaceutical Co., Ltd. Preparation of dihydropyranopyrimidine derivatives as Hedgehog signaling inhibitor. CN103910736; 2013
70. Jiangsu Simcere Pharmaceutical Co., Ltd. Preparation of heterocyclic compounds as hedgehog signaling path inhibitors. CN104003990; 2013
71. Xin M, Wen J, Tang F, et al. The discovery of novel N-(2-pyrimidinylamino) benzamide derivatives as Potent Hedgehog Signaling Pathway Inhibitors. Bioorg Med Chem Lett 2013;23:6777-83
72. Xin M, Wen J, Tang F, et al. Synthesis and evaluation of N-(2-pyrimidinylamino) benzamides inhibitors of hedgehog signaling pathway. Bioorg Med Chem Lett 2014;24:983-8
73. Xin M, Zhang L, Tang F, et al. Design, synthesis and evaluation of pyrrolo[2,1-f] [1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors. Bioorg Med Chem 2014;22:1429-40
74. Xin M, Zhang L, Shen H, et al. Design, synthesis, and biological study of 6,7-dihydro-5H-pyrano[2,3-d]pyrimidine derivatives as novel hedgehog signaling pathway inhibitors. Med Chem Res 2014;23:3784-92
75. Zhang L, Xin M, Shen H, et al. Five-membered heteroaromatic ring fused-pyrimidine derivatives: design, synthesis, and hedgehog signaling pathway inhibition study. Bioorg Med Chem Lett 2014;24:3486-92
76. Zhang L, Xin M, Wen J, et al. 4-(Pyrimidin-2-ylamino)benzamide derivatives: design, synthesis, and hedgehog signaling pathway inhibition study. Chin J Org Chem 2014;34:1407-16
77. Kunming Institute of Botany, Chinese Academy of Sciences, P. R. China. Application of rubia alata cyclopeptides as hedgehog signaling path inhibitor, and their preparation methods and application. CN103877562; 2014
78. Memorial Sloan-kettering Cancer Center, The Rochefeller University. Treatment of pancreatic and related cancers with 5-Acyl-6,7-dihydrothieno[3,2-c]pyridines. WO142253; 2013
79. Petrova E, Rios-Esteves J, Ouerfelli O, et al. Inhibitors of hedgehog acyltransferase block sonic hedgehog signaling. Nat Chem Biol 2013;9:247-9 .. This paper describes the identification of a series of small molecules that inhibit hedgehog signaling pathway vis inhibition of hedgehog acyltransferase.
80. Nanjing Huawei Pharmaceutical Science and Technology Development Co., Ltd. Preparation of multiple-target antitumor compounds and useful in the treatment of cancer. CN103923066; 2014
81. Nant Holdings IP, LLC. Preparation of cyclic sulfonamide derivatives as inhibitors of hedgehog signaling pathway. WO071298; 2014
82. President and Fellow of Harvard College. Modulators of hedgehog signaling pathway. US0274233; 2013 .. This patent describes a series of small molecules that inhibit hedgehog signaling pathway vis inhibition translocation of Smo to primary cilia.
83. Wang Y, Arvanites AC, Davidow L, et al. Selective identification of hedgehog pathway antagonists by direct analysis of smoothened ciliary translocation. ACS Chem Biol 2012;7:1040-8
84. Sichuan University. Preparation of signaling pathway inhibitors for treating tumors and osteoporosis. CN103040824; 2013
85. Wu TM, Wang DC, Xiang P, et al. Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists. Bioorg Med Chem Lett 2014;24:1426-31
86. Suzhou Yunxuan Pharmaceutical Co., Ltd. Aminothiazole-pyridine heterocyclic compounds as hedgehog pathway antagonists and their preparation, pharmaceutical compositions and use in the treatment of cancer. CN103524535; 2013
87. Suzhou Yunxuan Pharmaceutical Co., Ltd. Pyrimidine derivatives as hedgehog pathway antagonists and their preparation, pharmaceutical compositions and use in the treatment of cancer. CN103588771; 2013
88. Suzhou Yunxuan Pharmaceutical Co., Ltd. Preparation of pyridine heterocyclic compounds with hedgehog pathway antagonist activity. CN103923085; 2014
89. Xiaohu Z. Hedgehog pathway signaling inhibitors and therapeutic applications thereof. WO113191; 2014
90. Rohner A, Spilker ME, Lam JL, et al. Effective targeting of hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective smoothened antagonist that penetrates the blood-brain barrier. Mol Cancer Ther 2012;11:57-65
91. Betti M, Castagnoli G, Panico A, et al. Development of a scalable route to the SMO receptor antagonist SEN794. Org Process Res Dev 2012;16:1739-45
92. Lu W, Geng D, Sun Z, et al. Scaffold hopping approach to a new series of smoothened antagonist. Bioorg Med Chem Lett 2014;24:2300-4
93. Ma H, Lu W, Sun Z, et al. Design, synthesis, and structure-Activity-relationship of tetrahydrothiazolopyridine derivatives as potent smoothened antagonists. Eur J Med Chem 2015;89:721-32
94. The Board of Trustees of The Leland Stanford Junior University. Imidazo bicycle imminium compounds as antitumor agents. WO192301; 2013 .. This patent describes the a series of imidazo bicycle imminiums that inhibit hedgehog signaling pathway vis targeting Gli1.
95. The Regents of The University of California. Targeting Gli proteins in human cancer by small molecules. WO013190; 2013
96. The Regents of The University of California. Targeting Gli proteins in human cancer by small molecules. WO116651; 2014
97. Bosco-Clement G, Zhang F, Chen Z, et al. Targeting gli transcription activation by small molecule suppresses tumor growth. Oncogene 2014;33:2087-97 .. This paper describes the identification of a series of small molecules that inhibit hedgehog signaling pathway vis regulating Gli expression.
98. Yauch RL, Dijkgraaf GJP, Alicke B, et al. Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science 2009;326:572-4 .. This paper describes the identification of the first Smo mutants that confer resistance to hedgehog pathway inhibition with treatment of vismodegib.
99. Buonamici S, Williams J, Morriessey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010;2:51ra70
100. Wang CYY, Wei Q, Han I, et al. Hedgehog and notch signaling regulate self-renewal of undifferentiated pleomorphic sarcomas. Cancer Res 2012;72:1013-22
101. Jesus-Acosta AD, O'Dwyer PJ, Ramanathan RK, et al. A phase II study of vismodegib, a hedgehog (hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA). J Clin Oncol 2014;32(Suppl 3):abstract 257